CardioMEMS, the real progress in heart failure home monitoring.
Edoardo GrondaEmilio VanoliAlessandro ZorziDomenico CorradoPublished in: Heart failure reviews (2020)
The burden of hospitalizations driven by exacerbation of acute heart failure remains unacceptably high. The associated use of hospital resources drives increasing patient, caregiver, and economic costs. Noninvasive telemedical systems investigated in randomized controlled trials have failed to demonstrate to reduce hospitalization rates probably because of the indirect (non-linear) relationship of the measured biological signals with the patient congestion status. Instead, there is increasing evidence that direct measure of intracardiac and pulmonary artery pressure can effectively guide heart failure management and reduce hospitalizations. Early studies adopting implantable hemodynamic monitors in the right heart unveiled the potential of pressure-based heart failure management, whereas subsequent investigations showed the powerful preemptive approach for heart failure exacerbations. One large randomized trial (CHAMPION) proved that a direct pulmonary pressure monitor system (CardioMEMS) substantially reduced heart failure hospitalizations in subjects randomized to active pulmonary pressure-guided management. The system monitoring safety and efficacy were also excellent. The study proved that early management in response to increased pulmonary pressure is able to provide the most effective therapeutic intervention to prevent heart failure exacerbations.
Keyphrases
- heart failure
- acute heart failure
- pulmonary hypertension
- pulmonary artery
- chronic obstructive pulmonary disease
- left ventricular
- randomized controlled trial
- cardiac resynchronization therapy
- atrial fibrillation
- cystic fibrosis
- coronary artery
- pulmonary arterial hypertension
- healthcare
- case report
- clinical trial
- double blind
- systematic review
- left atrial appendage
- high resolution
- climate change
- atomic force microscopy
- study protocol
- meta analyses
- adverse drug
- electronic health record
- phase iii